MARKET

BCAX

BCAX

Bicara Therapeutics
NASDAQ
12.84
-0.16
-1.19%
Closed 16:00 01/14 EST
OPEN
13.03
PREV CLOSE
12.99
HIGH
13.44
LOW
12.33
VOLUME
458.94K
TURNOVER
--
52 WEEK HIGH
28.09
52 WEEK LOW
12.33
MARKET CAP
698.42M
P/E (TTM)
-39.9471
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCAX last week (0106-0110)?
Weekly Report · 1d ago
Weekly Report: what happened at BCAX last week (1230-0103)?
Weekly Report · 01/06 12:49
Weekly Report: what happened at BCAX last week (1223-1227)?
Weekly Report · 12/30/2024 12:39
Weekly Report: what happened at BCAX last week (1216-1220)?
Weekly Report · 12/23/2024 12:49
Weekly Report: what happened at BCAX last week (1209-1213)?
Weekly Report · 12/16/2024 12:51
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 12/09/2024 13:20
Weekly Report: what happened at BCAX last week (1202-1206)?
Weekly Report · 12/09/2024 12:49
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Acadia Healthcare (ACHC) and Bicara Therapeutics Inc. (BCAX)
TipRanks · 12/09/2024 11:20
More
About BCAX
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

Webull offers Bicara Therapeutics Inc. stock information, including NASDAQ: BCAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCAX stock methods without spending real money on the virtual paper trading platform.